Imugene Signs Swiss Drug Manufacturer to Speed Her-Vaxx Development

Me l b o u r n e , 15 Se p t e m b e r 2014 : Australian biopharmaceutical company Imugene Limited (ASX:IMU) has progressed the manufacture of its proprietary therapeutic HER-2+ cancer immunotherapy HER-Vaxx with the signing of a new contract with peptide company Bachem AG.
Bachem is a specialist in synthesising clinical grade peptides for inclusion and assembly into an immunotherapy delivery platform as needed for the manufacture of HER-Vaxx.
Bachem successfully completed a feasibility study earlier this year of the HER-Vaxx peptide (combining three individual peptide B-cell epitope antigens) and is now developing and validating analytical test methods used in the manufacture of clinical (GMP) grade HER-Vaxx, to be manufactured by Mymetics. The data generated is important content in the Investigator Brochure that will be part of Imugene's FDA IND submission.
HER-Vaxx is a therapeutic gastric & breast cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu, the same biomarker targeted by the US$6.9 billion per annum drug Herceptin®. HER-Vaxx successfully completed a Phase 1 study in breast cancer and the next stage of development will be a Phase 1b/2 gastric cancer study.
Gastric or stomach cancer is the second most common cause of cancer-related death in the world and the fourth most commonly diagnosed cancer with over 1 million new cases diagnosed each year.
Co n t a c t :
Charles Walker Paul A Hopper
Chief Executive Officer Executive Chairman
+61 450 446 990 +1 858 334 5820 (US)
cwalker[at]imugene.com +61 406 671 515 (Australia)
receptogen[at]earthlink.net

Me d i a c o n t a c t : Rudi Michelson

Monsoon Communications

+61 3 9620 3333 rudim[at]monsoon.com.au

Ab o u t I m u g e n e : Imugene (ASX; IMU) is an immuno-oncology biopharmaceutical company developing HER2 +ve gastric and breast cancer immunotherapies. The Company's lead product is HER-Vaxx, a proprietary HER2 +ve cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu. HER-2/neu is a known and validated receptor over-expressed on various tumours including gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer. Imugene's corporate headquarters are located in Melbourne, Australia with the scientific team in Vienna, Austria. For more information on Imugene, please visit www.imugene.com

Imugene Limited A.C.N: 009 179 551 Suite 1, 1233 High Street, Armadale, VIC, 3142 Phone: 03 9824 5254 Fax: 03 9822 7735
distributed by